Second Booster Dose Demonstrates Similar Immune Response to First Dose

  • Pfizer and Valneva report positive results from mid-stage trial of Lyme disease vaccine candidate VLA15
  • Immune response and safety profile similar after second booster dose to first dose
  • No approved human vaccines for Lyme disease currently
  • VLA15 advanced further in clinical development with two Phase 3 trials ongoing
  • Positive data brings vaccine closer to adults and children in endemic areas

Pfizer Inc. and French partner Valneva SE have reported positive results from a mid-stage trial of their Lyme disease vaccine candidate, VLA15. The Phase 2 trial demonstrated significant anamnestic antibody response across all age groups after the second booster dose. With no approved human vaccines for Lyme disease currently available, VLA15 is the furthest along in clinical development. Two Phase 3 trials are underway. If successful, the vaccine could be brought to adults and children living in endemic areas. Pfizer aims to submit a BLA to the FDA and European regulator by 2026.

Factuality Level: 9
Factuality Justification: The article provides accurate information about Pfizer and Valneva’s Lyme disease vaccine candidate VLA15’s Phase 2 trial results, cites relevant statistics on the prevalence of Lyme disease in the U.S. and Europe, and includes a quote from Valneva’s chief medical officer. It also mentions Moderna’s work on a similar vaccine. The article is not sensationalist or opinionated, and presents information without any apparent bias.
Noise Level: 2
Noise Justification: The article provides relevant information about the progress of a Lyme disease vaccine candidate and its positive results from a Phase 2 trial. It also mentions the number of people diagnosed with Lyme disease in the U.S. and Europe, as well as the potential timeline for regulatory submission. The article stays on topic and supports its claims with data.
Public Companies: Pfizer Inc. (PFE), Valneva SE (VLA)
Key People: Dr. Juan Carlos Jaramillo (chief medical officer at Valneva)

Track all markets on TradingView

Financial Relevance: Yes
Financial Markets Impacted: Pfizer’s stock market performance
Financial Rating Justification: The article discusses positive results from a mid-stage trial of Pfizer and Valneva SE’s Lyme disease vaccine candidate, VLA15. This has the potential to impact Pfizer’s stock market performance as they aim to submit a BLA to the FDA and European regulator in 2026, depending on Phase 3 data. The company’s stock has gained 0.8% year-to-date.
Presence Of Extreme Event: No
Nature Of Extreme Event: Other
Impact Rating Of The Extreme Event: Minor
Extreme Rating Justification: There is no extreme event mentioned in the article, but the development of a Lyme disease vaccine candidate is considered as a minor impact event as it does not have immediate or severe consequences for society.
Move Size: The market move size mentioned in this article is a 0.8% increase in Pfizer’s stock price.
Sector: Healthcare
Direction: Up
Magnitude: Small
Affected Instruments: Stocks

Image source: Arne Müseler
 /

Reported publicly: www.marketwatch.com